A Multicentre, Phase 2, Randomised Study to Assess the Efficacy and Safety of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients
Latest Information Update: 24 Aug 2022
At a glance
- Drugs Bemcentinib (Primary) ; Dexamethasone; Remdesivir
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Sponsors BerGenBio
- 13 Oct 2021 Status changed from active, no longer recruiting to completed.
- 12 Jul 2021 Results of combined analysis from this and NCT04890509 studies presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2021.
- 12 Jul 2021 Combined analysis of data from this and NCT04890509 studies published in the BerGenBio Media Release.